For a patient with a high-grade acute cellular rejection demonstrated by biopsy, the most suitable treatment option is?

For a patient with a high-grade acute cellular rejection demonstrated by biopsy, the most suitable treatment option is?

• A. Prednisone 50 mg by mouth
• B. Admit and give methylprednisolone 1000 mg intravenously
• C. Admit and provide antithymocyte globulin
• D. Admit and administer intravenous immunoglobulin

Answer: (C)

For a patient experiencing high-grade acute cellular rejection demonstrated by biopsy, the most suitable treatment option is antithymocyte globulin. Antithymocyte globulin is an effective immunosuppressant that is specifically used in cases of severe or high-grade rejection. It works by depleting T-lymphocytes, the key mediators of acute cellular rejection, thereby reducing the immune response against the transplanted organ. Using antithymocyte globulin is particularly beneficial in acute cellular rejection situations because it provides a broad immunosuppressive effect, allowing for rapid intervention, especially when the rejection is significant enough to threaten the viability of the transplanted organ. While intravenous steroids like methylprednisolone may be considered in acute cellular rejection management, in cases deemed high-grade, antithymocyte globulin is often preferred due to its potency and duration of action. The other treatment options mentioned, such as intravenous immunoglobulin, are generally not the first-line therapy for high-grade acute cellular rejection and typically serve different roles in rejection management or other transplant-related issues.

For a patient experiencing high-grade acute cellular rejection demonstrated by biopsy, the most suitable treatment option is antithymocyte globulin. Antithymocyte globulin is an effective immunosuppressant that is specifically used in cases of severe or high-grade rejection. It works by depleting T-lymphocytes, the key mediators of acute cellular rejection, thereby reducing the immune response against the transplanted organ.

Using antithymocyte globulin is particularly beneficial in acute cellular rejection situations because it provides a broad immunosuppressive effect, allowing for rapid intervention, especially when the rejection is significant enough to threaten the viability of the transplanted organ.

While intravenous steroids like methylprednisolone may be considered in acute cellular rejection management, in cases deemed high-grade, antithymocyte globulin is often preferred due to its potency and duration of action. The other treatment options mentioned, such as intravenous immunoglobulin, are generally not the first-line therapy for high-grade acute cellular rejection and typically serve different roles in rejection management or other transplant-related issues.